Video Experimental Relacionado
Updated: Nov 9, 2025
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.5K
La dama de honor del islote se convierte en la novia: los péptidos derivados del proglucagón proporcionan terapias
1MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK.
Cell
|April 8, 2021
Resumen
Los investigadores descubrieron nuevos péptidos del proglucagón, lo que condujo a tratamientos para la diabetes tipo 2. Estos descubrimientos de péptidos ofrecen beneficios para la salud global para los trastornos metabólicos.
Área de la Ciencia:
- Endocrinología y Metabolismo
- Biología molecular
- Farmacología
Sus antecedentes:
- El gen del proglucagón codifica múltiples hormonas peptídicas.
- Comprender las funciones fisiológicas de estos péptidos es crucial para la investigación de enfermedades metabólicas.
Objetivo del estudio:
- Para destacar el descubrimiento de nuevos péptidos de la secuencia de proglucagón.
- Para establecer el significado fisiológico de estos péptidos recién identificados.
Principales métodos:
- Secuenciación genética para identificar nuevos péptidos.
- Estudios fisiológicos para determinar las funciones del péptido.
- Investigación clínica para evaluar el potencial terapéutico.
Principales resultados:
- Identificación de péptidos previamente desconocidos dentro de la secuencia de proglucagón.
- Elucidación de las funciones fisiológicas específicas de estos nuevos péptidos.
- Validación de estos péptidos como objetivos para el desarrollo terapéutico.
Conclusiones:
- El descubrimiento de péptidos derivados del proglucagón ha avanzado significativamente en la investigación de enfermedades metabólicas.
- Estos hallazgos han llevado al desarrollo de terapias efectivas para la diabetes tipo 2 y afecciones relacionadas.
- El trabajo de Drucker, Habener y Holst ha tenido un impacto mundial en la atención al paciente.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
538
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
538
01:15Hypoglycemia and Glucagon
511
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
511
01:16Hormones Regulating Blood Glucose
5.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
5.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
327
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
327
01:25Insulin: Biosynthesis, Chemistry, and Preparation
781
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
781
01:06Oral Hypoglycemic Agents: Glinides
372
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
372